“…Strength of the overall body of evidence was assessed using a modified GRADE. RESULTS: Thirty eight studies (n>50,000) which were conducted across a range of countries were included. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: Participants were recruited to be part of a STEM open house. Thirty-five students participated in the Undergraduate Research Experiences: Mentoring, Awareness, and Perceptions Survey (URE MAPS). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Proptosis response was similar to the primary outcome, with 55% of those receiving teprotumumab having a high response (≥3mm decrease). Gender, race, smoking or baseline proptosis values did not impact proptosis response. …”
Enlace del recurso
Enlace del recurso

“…METHODS AND RESULTS: Thirty‐five patients [median age 40 (range 18–70) years, mean body mass index 23.8 ± 4.2 kg/m(2), 31% male] with ME/CFS were studied for peripheral endothelial function assessed by peripheral arterial tonometry (EndoPAT2000). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The association analysis using GLM and MLM models led to the identification of 30 and 10 SSR markers associated with 70 and 16 QTLs, respectively. Thirty novel QTLs linked with 16 SSRs were identified to be associated with eleven traits, namely tiller number (qTL-6.1, qTL-11.1, qTL-4.1), panicle length (qPL-1.1, qPL-5.1, qPL-7.1, qPL-8.1), flag leaf length (qFLL-8.1, qFLL-9.1), flag leaf width (qFLW-6.2, qFLW-5.1, qFLW-8.1, qFLW-7.1), total no. of grains (qTG-2.2, qTG-a7.1), thousand-grain weight (qTGW-a1.1, qTGW-a9.2, qTGW-5.1, qTGW-8.1), fertile grains (qFG-7.1), seed length-breadth ratio (qSlb-3.1), plant height (qPHT-6.1, qPHT-9.1), days to 50% flowering (qFD-1.1) and grain yield per se (qYLD-5.1, qYLD-6.1a, qYLD-11.1).Some of the SSRs were co-localized with more than two traits. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…MAIN OUTCOMES AND MEASURES: The difference in survival benefit of ICIs between sex, age (<65 vs ≥65 years), and ECOG PS (0 vs ≥1), as well as the difference stratified by cancer type, line of therapy, agent of immunotherapy, and immunotherapy strategy in the intervention arm. RESULTS: Thirty-seven phase 2 or 3 randomized clinical trials involving 23 760 patients were included. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…It also investigates the underlying changes in plasma under such conditions, based on the integrative analysis of indirect calorimetry and non-target metabolomics profiling. Thirty-six barrows with initial BW of 26.4 ± 1.9 kg and 24 barrows with initial BW of 64.2 ± 3.1 kg were successively allotted to six respiration chambers with ambient temperatures set as 18 °C, 21 °C, 23 °C, 27 °C, 30 °C, and 32 °C, and four respiration chambers with ambient temperatures set as 18 °C, 23 °C, 27 °C, and 32 °C, respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The purpose of this study was to systematically evaluate pp-nTMS with biphasic pulses in comparison to conventionally used sp-nTMS for preoperative motor mapping of lower extremity (lE) muscle representations. Thirty-nine patients (mean age: 56.3 ± 13.5 years, 69.2% males) harboring motor-eloquent brain lesions of different entity underwent motor mapping of lE muscle representations in lesion-affected hemispheres and nTMS-based tractography of the corticospinal tract (CST) using data from sp-nTMS and pp-nTMS with biphasic pulses, respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Results: 465 studies were retrieved. Thirty (6.4%) studies including 3985 patients met all selection criteria. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Compared with the low-risk score group, early growth response-1 (EGR1), CACNA2D1, AC005831.1, SLC52A3, TMEM79, IL20RA, CRACR2A, and FAM189A2 expressions in the high-risk score group were decreased, while AC012181.1 and TRAPPC8 expressions were increased. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The proportion of cases of RCSI was significantly higher in the stratified care arm compared with the stepped care arm (264 of 505 [52.3%] vs 134 of 297 [45.1%]; odds ratio, 1.40 [95% CI, 1.04-1.87]; P = .03). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Malignant (cancerous) tumors predominated, and the snakes with these tumors were significantly more likely to die of their cancer than those with benign tumors. Thirty-six of the 133 snakes received treatment for their tumors. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Enhanced arterial spin labeling (eASL) imaging was performed using a 3.0-T GE magnetic resonance imaging scanner, and all patients underwent carotid and vertebral Doppler ultrasound examinations. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Our outcomes of interest were (1) hospitalization with infection present on admission (POA); (2) hospitalization with infection as the primary cause; and (3) 30-day mortality following hospitalization with infection as the primary cause. …”
Enlace del recurso
Enlace del recurso

“…The mean RPE CR-10 score for the six-minute walk test was 3 ± 2.5 (range 0–10) vs a mean RPE CR-10 score of 10 ± 0 for the Modified Bruce treadmill test. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Level of Evidence: Level III, case-control study.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Fifty-one patients were identified via referral. Thirty-two patients received medication, of whom 8 (25%) were identified by screening plus outreach alone. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Bona fide intestinal T(RM) generation 3. Bona fide intestinal T(RM) function METHOD: To address the effects of NOD2-signalling on intestinal T-cell priming in vivo, wildtype (WT) mice were adoptively transferred 50,000 naïve LCMV-specific (SMARTA) CD4(+) T-cells. …”
Enlace del recurso
Enlace del recurso

“…The median OS, progression-free survival (PFS), and time to treatment failure (TTF) were 12.9 (95% CI 11.6–14.8), 5.7 (95% CI 5.0–7.0), and 4.3 (95% CI 3.9–5.7) months, respectively, for all patients; 13.4 (95% CI 9.5–16.0), 5.8 (95% CI 4.1–7.8), and 5.3 (95% CI 3.5–7.2) months in the original-dose group; and 12.8 (95% CI 11.3–15.3), 5.7 (95% CI 4.4–7.0), and 4.1 (95% CI 3.7–5.7) months in the reduced-dose group. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso